MedTrace Logo

Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis

NCT03052101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2024-01-31

Study results available
· View outcomes & findings →

Summary

The aim of this study is to conduct survey-based assessments for the safety of air travel in patients with pulmonary Langerhans cell histiocytosis (PLCH). The study will enroll patients through the clinic network at Rare Lung Disease Consortium (RLDC) and through the Histiocytosis Association website. Patients will have access to the questionnaire via REDCap (an online data management system) and each patient will be provided with a link to complete the survey. The investigators plan on enrolling approximately 200 patients with PLCH for the purpose of this study. Secondary aims of this study include further characterization of the clinical aspects of disease and to establish a contact registry for these patients, in order to facilitate future studies.

Conditions

  • Pulmonary Langerhans Cell Histiocytosis

Sponsors & Collaborators

  • Rare Diseases Clinical Research Network

    collaborator NETWORK

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Cincinnati

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052101 on ClinicalTrials.gov